Roth Capital Initiates Buy On Bluebird Bio; Sees 38% Upside For The Stock
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay initiated coverage on Bluebird Bio (NASDAQ:BLUE) with a Buy rating and a $50 price target, which represents a potential upside of 38% from where the stock is currently trading.
Chattopadhyay noted, “bluebird bio, Inc., is one of the pioneers of gene therapy . With its proprietary Lentiviral vectors, the company has successfully corrected dysfunctional genes and is well-positioned to deliver single treatment-based curative therapies for multiple monogenic diseases, in our view. Despite high transduction efficiency achieved in recent clinical studies, molecular clonality studies have not indicated increased risk of mutagenesis.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 3.3% and a 36.7% success rate. Chattopadhyay has an average return when recommending BLUE, and is ranked #1540 out of 3293 analysts.